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Metabolic Syndrome (Mets) and increased serum uric acid (SUA), are well known renal risk
predictors and often coexist in patients with type 2 diabetes (T2D). Whether they indepen-
dently contribute to the onset of CKD is at present unclear.
Methods and results
Within the AMD Annals database we identified patients with T2D and normal renal function
and urine albumin excretion at baseline and regular follow-up visits during a 4-year period.
Blood pressure, BMI, HDL, triglycerides, and SUA were available in 14,267 patients. The
association between Mets and/or hyperuricemia (HU, top fifth gender specific quintile) and
the occurrence of renal outcomes were evaluated.
Results
At baseline 59% of patients (n = 8,408) showed Mets and 18% (n = 2,584) HU. Over the
4-year follow-up, 14% (n = 1,990) developed low eGFR (i.e. below 60 mL/min/1.73 m2),
and 26% (n = 3,740) albuminuria. After adjustment for confounders, BP130/85, low HDL,
triglycerides150 and HU were independently related to the development of low eGFR
(1.57, P<0.001; 1.13, P = 0.056; 1.18, P = 0.008; 1.26, P = 0.001) and of albuminuria (1.35,
P<0.001; 1.18, P = 0.001; 1.15, P = 0.002; 1.24, P = 0.001), respectively.
The incidence of low eGFR was higher in patients with HU independent of the presence
or absence of Mets (21%, OR 1.30, p = 0.009 and 20%, 1.57, p<0.000 respectively), while
albuminuria occurred more frequently in those with Mets and HU (32%, OR 1.25, p = 0.005)
as compared to the reference group.
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Conclusions
HU and Mets are independent predictors of CKD and its individual components in patients
with T2D.
Introduction
Chronic kidney disease (CKD) is becoming a major global public health concern and its preva-
lence and incidence are steadily increasing mostly because of the rising burden of type 2 diabe-
tes (T2D) and obesity worldwide [1].
Metabolic Syndrome (Mets) is widely prevalent among patients with CKD and has been
reported to play a role in the progression of renal damage [2, 3] and development of end stage
renal disease (ESRD) [4]. Moreover, Mets is increasingly recognized as an important predictor
for de novo incidence of CKD, largely based on studies conducted among non diabetic popula-
tions from different ethnic groups [5–8]. So far, only one prospective study [9] conducted
among Chinese patients with T2D investigated the relationship between Mets and the inci-
dence of eGFR<60 mL/min/1.73 m2. A few studies examined the associations of Mets and the
risk for albuminuria or proteinuria [10–14] but none among patients with diabetes.
Mets is also associated with hyperuricemia [15], which has been shown by some although
not all studies to independently predict the onset and progression of CKD in several clinical
settings, including T2D [16, 17, 18]. The associations between each individual component of
Mets and outcomes have been reported to vary in the literature but are not thought to be suffi-
cient to account for the increased hazard of CKD usually associated with Mets. It has been
proposed that the components of Mets may foster the progression of renal damage mainly
through the coexistence of several underlying pathological mechanisms such as increased oxi-
dative stress, chronic inflammation, increased fibrogenic activity, and endothelial dysfunction
[19]. Nevertheless, a causal relationship has not been proven and more studies are needed to
precisely elucidate the mechanisms linking Mets to the development of renal damage.
The primary focus of this analysis was to examine the independent and joint associations of
Mets, its components and increased SUA levels with risk of incident CKD and its components
during a four year follow-up within a large registry of adults with T2D from across Italy.
1. Methods
1.1. Study setting, patients and data sources
The study database is representative of a large cohort of patients with T2DM followed-up at
131 diabetes centers in Italy and participating in the Italian Association of Clinical Diabetolog-
ists (Associazione Medici Diabetologi, AMD) initiative. The analysis was performed using
electronic medical records collected between 1st January, 2004 and 30th June, 2008. For the
purpose of the analysis, we considered only patients18 years old and with a follow-up evalu-
ation within 48±6 months complete for data about body mass index (BMI), blood pressure
(BP) values, HDL-cholesterol, triglycerides, SUA, estimated GFR (eGFR) and urinary albumin
excretion and information on treatment. Of 31,480 patients identified, we excluded 17,213
patients for the reasons detailed in S1 Fig. Fourteen-thousands-two-hundred-sixty-seven
patients with T2D and from 69 clinics constitute the study population. The centers involved in
the study were homogeneously distributed throughout the country.
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Methods and data collection
As previously reported [17,20], the Italian Association of Clinical Diabetologists (Associa-
zione Medici Diabetologi, AMD) initiative and the relative database was established in
order to identify a set of indicators that can be used in the context of continuous quality
improvement. Participating centres adopted the same software systems for everyday man-
agement of outpatients, while a specially developed software package allowed us to extract
the information we intended to analyze from all the clinical databases (AMD Data File).
Moreover, data from all participating centers were collected and centrally analyzed anony-
mously [17,20].
This initiative includes measuring and monitoring HbA1c, BP, low-density lipoprotein
(LDL-c), total and high density lipoprotein cholesterol (HDL-c) and triglycerides. The use of
specific classes of drugs (insulin, statins and two or more anti-hypertensive agents) was also
evaluated. Since normal ranges for HbA1c varied among centers, the percentage change with
respect to the upper normal value (measured value/upper normal limit) was estimated and
multiplied by 6.0 in order to allow comparisons among the centers. Kidney function was
assessed by serum creatinine and urinary albumin excretion measurements. GFR was esti-
mated for each patient using a standardized serum creatinine assay and the Chronic Kidney
Disease Epidemiology Collaboration formula [21]. Increased urinary albumin excretion (i.e.
albuminuria) was diagnosed if urinary albumin concentration was >30 mg/l, or if urinary
albumin excretion rate was >20 μg/min, or if urinary albumin-to-creatinine ratio (ACR) was
>2.5 mg/mmol in men and >3.5 mg/mmol in women.
At each participating centre all patients underwent physical examination and BP measure-
ments according a standardized protocol. BP was measured with the patient in the sitting posi-
tion after a 5-minute rest, with a mercury sphygmomanometer. Systolic BP and diastolic BP
were read to the nearest 2 mmHg. Disappearance of Korotkoff sounds (phase V) was the crite-
rion for diastolic BP. Three measurements were taken at 2-minute intervals and the average
value was used to define clinical systolic BP and diastolic BP.
Metabolic syndrome. The revised definitions of the National Cholesterol Education Pro-
gram-Adult Treatment Panel III, which suggests using BMI to define metabolic syndrome
when waist circumference data are not readily available has been used in the present study.
Accordingly, we did consider BMI30 kg/m2 as a risk factor, because this value approximates
a waist circumference >102 cm in men and>88 cm in women Since all study patients had
T2D, Metabolic syndrome was defined as the presence of two or more of the following compo-
nents: BMI30 kg/m2, serum triglycerides150 mg/dl or on treatment with fibrates, HDL
<50 mg/dl in women and<40 mg/dl in men, hypertension (BP130/85 mmHg or on antihy-
pertensive medications) [22].
As expected mean serum uric acid (SUA) levels were significantly higher in men as com-
pared to women (5.3 ±1.5 vs 4.8±1.7, P < 0.001). Therefore, we analyzed the study cohort on
the basis of gender specific quintiles of SUA. Hyperuricemia (HU) was defined as the presence
of SUA values in the range of the top gender specific SUA quintile (>5.8 mg/dL if female and
>6.4 mg/dL if male).
CKD was defined as albuminuria or low eGFR (i.e. <60 mL/min/1.73 m2) or both.
Each patient have been followed- up for 4 years, underwent multiple regular visits within
this timeframe Data on blood pressure, albuminuria and eGFR were collected on a yearly basis
over the entire study period. In case a given patient reached any of the pre-specified renal end
point before end of study, only data collected before the onset of that specific endpoint were
considered.
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Renal outcomes
The outcomes were: i. eGFR<60 mL/min/1.73 m2; ii. Albuminuria; a composite of either
eGFR<60 mL/min/1.73 m2 or Albuminuria.
Exposure
The main analysis aimed at evaluating the association between baseline presence of Mets, its
components, and HU and the incidence of renal outcomes during the study period.
Statistical analysis
Data are given as mean values ± standard deviation (SD); categorical variables are described as
frequencies and percentages. Variables associated to renal outcomes were evaluated by using
logistic regression mixed models with diabetes clinics fitted as random effect to consider possi-
ble differences in data across centers. Odds ratios (ORs) were reported with their 95% confi-
dence intervals (95% CIs). Multivariate models were fitted including patients with all data
available. The analyses were made using STATA software, Version 14 (StataCorp, College Sta-
tion, Texas). P values of<0.05 were considered statistically significant.
2. Results
Main clinical features of the study cohort at baseline, overall and on the basis of the presence/
absence of Mets and HU, are summarized in Table 1. The mean age was 63±10 years, 56% of
patients were males and the mean duration of diabetes was 10±8 years. By study design all
patients had normal urine albumin excretion, eGFR was 87±13 mL/min/1.73m2. Mets was
present in 59% (n = 8408) and HU in 18% (n = 2584) of patients, the average BP was 137±17/
80±9 mmHg, with 88% of patients showing either systolic or diastolic values above 130/85
mmHg or BP treatment, the average HDL was 52±15 mg/dL, with 29% of patients showing
HDL < 40 if male or < 50 mg/dL if female, the average triglycerides was 136±92 mg/dL with
31% of patients showing triglycerides150 mg/dL or on fibrates, the average BMI was 29±5
Kg/m2 with 38% of patients with BMI 30 Kg/m2 at the baseline visit. Patients with baseline
Mets and/or HU had a worse risk profile, namely higher BMI, BP values and a more unfavour-
able lipid profile despite lower disease duration and greater burden of antihypertensive and
lipid lowering treatment.
Baseline clinical features of patients grouped on the basis of SUA levels and individual com-
ponents of Mets are reported in S1 Table.
Patients in the top gender specific SUA quintile (n = 2,584) showed a worse clinical and
metabolic profile at baseline. They were older, had higher BMI, BP values, lower GFR values
and a worse lipid profile. They were more likely to have Mets (74% vs 56%, p<0.001) and a
good glycemic control despite a lower prevalence of insulin treatment.
As expected, despite being more frequently females, patients with Mets (n = 8408) showed
higher BP values, an unfavorable metabolic profile (included higher HbA1c) and significantly
higher SUA levels (5.3±1.5 vs 4.8±1.6, P<0.001) as compared to those without Mets. There
was no difference in age and eGFR on the basis of presence/absence of Mets.
Being in the top gender-specific uric acid quintile (HU) doubled the risk of having MS (OR
2.32 95% CI 2.10–2.56, P<0.001) even after adjusting for several variables, including HbA1c,
known duration of diabetes and eGFR.
Within 4-year follow-up, 1,990 (13.9%) patients developed eGFR<60 mL/min/1.73 m2,
3,740 (26.2%) albuminuria, and 5,041 (35%) CKD (i.e., eGFR <60 mL/min/1.73 m2 and/or
albuminuria). In S2 and S3 Figs. renal outcomes are reported as stratified by number of Mets
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Table 1. Clinical characteristics of study patients on the basis of the presence/ absence of metabolic syndrome and hyperuricemia (top gender-
specific quintile).
Metabolic syndrome No Yes No Yes
SUA in the top gender-specific quintile No No Yes Yes
All patients
n = 14267
n = 5179 n = 6504 n = 680 n = 1904
Metabolic syndrome 8408 (58.9%) - - - -
BP130/85 or BP treatment 12509 (87.7%) 3895 (75.2%) 6219 (95.6%) 558 (82.1%) 1837 (96.5%)
Low HDL 4199 (29.4%) 174 (3.4%) 3071 (47.2%) 14 (2.1%) 940 (49.4%)
Triglycerides150 mg-dl or fibrates 4430 (31.1%) 172 (3.3%) 3204 (49.3%) 28 (4.1%) 1026 (53.9%)
BMI>30 Kg/m2 5489 (38.5%) 147 (2.8%) 3969 (61.0%) 18 (2.6%) 1355 (71.2%)
Only diabetes 853 (6.0%) 791 (15.3%) 0 (0%) 62 (9.1%) 0 (0%)
Diabetes and 1 factor 5006 (35.1%) 4388 (84.7%) 0 (0%) 618 (90.9%) 0 (0%)
Diabetes and 2 factors 4633 (32.5%) 0 (0%) 3758 (57.8%) 0 (0%) 875 (46.0%)
Diabetes and 3 factors 2745 (19.2%) 0 (0%) 2037 (31.3%) 0 (0%) 708 (37.2%)
Diabetes and 4 factors 1030 (7.2%) 0 (0%) 709 (10.9%) 0 (0%) 321 (16.9%)
SUA (mg/dL) 5.1±1.6 4.5±1 4.8±.9 7.2±3.1 7.1±1.8
SUA in the top gender-specific quintile 2584 (18.1%) 0 (0%) 0 (0%) 680 (100%) 1904 (100%)
Male sex 8040 (56.4%) 3206 (61.9%) 3381 (52.0%) 465 (68.4%) 988 (51.9%)
Age (years) 63±10 63±11 63±9 65±9 63±9
Known duration of diabetes (years) 10±8 11±9 9±8 9±8 8±7
BMI (Kg/m2) 29±5 26±3 31±5 27±2 33±5
Serum creatinine (mg/dL) 0.83±0.16 0.83±0.16 0.82±0.16 0.9±0.17 0.88±0.17
eGFR (mL/min/1.73 m2) 87±13 88±13 88±13 82±13 82±14
HbA1c (%) 7.2±1.3 7.1±1.2 7.4±1.3 6.8±1 7.1±1.1
HbA1c7% 7535 (53.2%) 2646 (51.3%) 3712 (57.6%) 254 (37.9%) 923 (48.9%)
Total cholesterol (mg/dL) 189±37 188±35 188±38 186±37 192±38
Triglycerides (mg/dL) 136±92 95±42 160±105 102±36 177±109
HDL (mg/dL) 52±15 59±14 47±14 57±13 46±13
LDL (mg/dL) 111±33 111±32 111±33 109±33 113±34
LDL100 mg/dL 8808 (62.2%) 3255 (62.9%) 3964 (61.5%) 405 (59.9%) 1184 (63.4%)
Systolic BP (mmHg) 137±17 134±18 139±17 135±18 139±17
Diastolic BP (mmHg) 80±9 78±8 81±9 78±9 81±9
BP140/85 mmHg 7928 (55.6%) 2427 (46.9%) 4031 (62.0%) 339 (49.9%) 1131 (59.4%)
Retinopathy 2643 (18.5%) 963 (18.6%) 1264 (19.4%) 106 (15.6%) 310 (16.3%)
Smokers 1631 (17.2%) 603 (17.1%) 801 (18.8%) 53 (11.7%) 174 (14.2%)
Lipid-lowering treatment 6585 (46.2%) 2093 (40.4%) 3219 (49.5%) 302 (44.4%) 971 (51.0%)
Treatment with statins 6035 (42.3%) 2052 (39.6%) 2844 (43.7%) 290 (42.6%) 849 (44.6%)
Treatment with fibrates 321 (2.2%) 7 (.1%) 255 (3.9%) 1 (0.1%) 58 (3.0%)
Antihypertensive treatment 8961 (62.8%) 2461 (47.5%) 4551 (70.0%) 435 (64.0%) 1514 (79.5%)
Treatment with ACE-Is/ARBs 7464 (52.3%) 2009 (38.8%) 3808 (58.5%) 358 (52.6%) 1289 (67.7%)
Aspirin 4101 (28.7%) 1368 (26.4%) 1944 (29.9%) 193 (28.4%) 596 (31.3%)
Antidiabetic therapy
Diet 1547 (10.8%) 652 (12.6%) 581 (8.9%) 116 (17.1%) 198 (10.4%)
Oral antidiabetic drugs 9563 (67.0%) 3256 (62.9%) 4459 (68.6%) 455 (66.9%) 1393 (73.2%)
Oral antidiabetic drugs and insulin 1726 (12.1%) 544 (10.5%) 925 (14.2%) 55 (8.1%) 202 (10.6%)
Insulin 1431 (10.0%) 727 (14.0%) 539 (8.3%) 54 (7.9%) 111 (5.8%)
Mean±SD or absolute frequency (percentage). ACE-Is, angiotensin converting enzyme-inhibitors; ARBs, angiotensin II receptor antagonists; BMI, body
mass index; BP, blood pressure; eGFR, estimated glomerular filtration rate; HbA1c, glycated haemoglobin; HDL, high-density lipoprotein cholesterol; LDL,
low-density lipoprotein cholesterol; SUA, serum uric acid; Gender specific highest quintile according to the baseline serum uric acid levels: 5.8 mg/dL in
females and 6.4 mg/dL in males). Patients’ baseline missing data: known duration of diabetes in 212 (1.5%), HbA1c in 115 (0.8%), total cholesterol in 21
(0.1%), and smoking status in 4808 (33.7%).
https://doi.org/10.1371/journal.pone.0176058.t001
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components and presence of Mets. There was a progressive increase of incident low eGFR (i.e.
eGFR<60 mL/min/1.73m2) and albuminuria across the five subgroups (from 5.7 to 17.6%,
and from 17.8 to 30.7%, 0 vs. 4 components beyond diabetes, respectively). Patients with Mets
at baseline developed reduced eGFR and albuminuria more frequently as compared to those
without Mets (15.6 vs 11.6% and 28.2 vs 23.4%, p<0.001 respectively). Moreover, patients with
HU at baseline developed reduced eGFR and albuminuria more frequently as compared to
those without HU (20.9 vs 12.4% and 30 vs 25.4%, p<0.001 respectively).
At univariate analysis, patients with each single Mets component or with HU reached low
eGFR and albuminuria significantly more frequently than those without it (S2 Table). Among
different components of the Mets, BP had the greatest impact on the incidence of measures of
CKD (OR 3.05 95% CI 2.46–3.77, P<0.001 for low eGFR and OR 1.62 95% CI 1.41–1.85,
P<0.001 for albuminuria, respectively).
The independent association of several variables with renal outcomes at four year follow-
up, was further investigated by logistic multivariate analysis among all and separately for males
and females. In the general cohort and in males, SUA levels and metabolic components (with
the exception of diastolic BP) strongly and significantly predicted the development of low
eGFR and albuminuria, independently of a number of potential confounders, included base-
line eGFR and HbA1c (S3 Table). Among females, the risk for the onset of low eGFR was sig-
nificantly and independently associated to BMI and SUA levels at baseline, while the risk for
the incidence of albuminuria was linked with a decrease in diastolic BP and HDL values fur-
ther than with an increase in BMI and SUA levels. We further examined the associations of
HU and individual components of Mets and the risk for new onset of low eGFR and albumin-
uria in a similar model among all with a dichotomous approach: the presence of BP130/85,
low HDL, Triglicerydes150, BMI30 and HU independently increased the risk for eGFR
<60 ml/min/1.73m2 (1.57, P<0.001; 1.13, P = 0.056; 1.18, P = 0.008; 1.21, P0.002; 1.26,
P = 0.001) and for albuminuria (1.35, P<0.001; 1.18, P = 0.001; 1.15, P = 0.002; 1.24, P = 0.001;
1.17, P = 0.004) respectively. Finally, when Mets (and not its components) was included in the
model, the presence of Mets and of HU, independently predicted the development of eGFR
(1.41, P<0.001; 1.29, P<0.001, respectively) and albuminuria (1.33, P<0.001; 1.21, P<0.001,
respectively).
We performed further analyses after classifying patients into four sub-groups on the basis
of the presence/absence of HU and MS (Fig 1A and 1B, Table 2). Fig 1A and 1B show the inci-
dence of GFR reduction and albuminuria according to this stratification. The incidence of low
eGFR was higher for patients with HU independent of the presence or absence of Mets as com-
pared to those without HU and Mets (21% and 20% vs 10.4%, p<0.001 respectively). The inci-
dence of albuminuria was higher for patients with Mets and HU as compared to reference
(those without HU and Mets) (32 vs 23%, p<0.001). In those without Mets, HU did not influ-
ence the risk to develop albuminuria.
Having HU was the stronger independent risk factor for the development of low eGFR with
an OR ranging from 1.3 to 1.57 according to the presence of Mets or not. Furthermore, HU
showed a significant, additive role to the presence of Mets in the risk for the onset of albumin-
uria which increased significantly (by 25%) only for patients with Mets and HU as compared
to those without Mets and HU (95% CI 1.07–1.46, P<0.001) (Table 2).
3. Discussion
Our data provide new insights into the complex relationship between SUA, Mets and the inci-
dence of CKD in a large longitudinal cohort study of T2D patients treated in accordance with
evidence based guidelines.
Metabolic syndrome, uric acid and DKD incidence
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Patients with HU were 2 times more likely to concomitantly show Mets. The odds of devel-
oping eGFR <60 ml/min per 1.73 m2 and albuminuria during follow-up increased along with
the number of components of Mets from 0 to 4 beyond diabetes. Furthermore, Mets and HU
Fig 1. 1A. Incidence of GFR reduction on the basis of the presence/absence of metabolic syndrome and hyperuricemia (top gender-specific quintile)1B.
Incidence of albuminuria on the basis of the presence/absence of metabolic syndrome and hyperuricemia (top gender-specific quintile)
https://doi.org/10.1371/journal.pone.0176058.g001
Table 2. Determinants of measures of renal outcome including the presence/absence of Metabolic Syndrome and/or Hyperuricemia.
eGFR <60 mL/min/1.73m2 Albuminuria
OR (95%CI) p OR (95%CI) p
1HU-Mets- Reference - Reference -
2HU-Mets+ 1.16 (0.99–1.36) 0.069 1.02 (0.91–1.14) 0.766
3HU+Mets- 1.57 (1.23–1.99) <0.001 1.00 (0.81–1.22) 0.964
4HU+Mets+ 1.30 (1.07–1.59) 0.009 1.25 (1.07–1.46) 0.005
Systolic BP (by 10 mmHg) 1.07 (1.03–1.11) <0.001 1.06 (1.03–1.09) <0.001
Diastolic BP (by 10 mmHg) 0.92 (0.85–0.99) 0.034 0.96 (0.90–1.02) 0.164
HDL (by 5 mg/dL) 0.97 (0.95–0.99) 0.006 0.96 (0.95–0.98) <0.001
Triglycerides (by 50 mg/dL) 1.06 (1.03–1.09) <0.001 1.03 (1.01–1.05) 0.013
BMI (by 5 Kg/m2) 1.11 (1.04–1.19) 0.002 1.10 (1.05–1.16) <0.001
Male sex 0.76 (0.67–0.85) <0.001 1.37 (1.25–1.49) <0.001
Age (by 10 years) 1.53 (1.41–1.65) <0.001 1.19 (1.13–1.26) <0.001
Known duration of diabetes (by 10 years) 1.11 (1.03–1.18) 0.003 1.02 (0.97–1.08) 0.398
eGFR (by 10 mL/min/1.73 m2) 0.40 (0.38–0.42) <0.001 1.01 (0.97–1.04) 0.791
HbA1c (by 1%) 1.12 (1.07–1.18) <0.001 1.12 (1.08–1.16) <0.001
Multivariate models. BMI, body mass index; BP, blood pressure; eGFR, estimated glomerular filtration rate; HbA1c, glycated haemoglobin; HDL, high-
density lipoprotein cholesterol; HU, serum uric acid in the top gender-specific quintile; LDL, low-density lipoprotein cholesterol; Mets, Metabolic syndrome.
Complete-case analysis performed excluding 273 patients with incomplete data.
https://doi.org/10.1371/journal.pone.0176058.t002
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emerged as independent risk factors for the development of both low eGFR and albuminuria;
the former was more likely to occur in the presence of HU at baseline, whereas the incidence
of albuminuria was significantly increased only in those patients simultaneously presenting
HU and Mets at baseline.
To the best of our knowledge, this is the first time that longitudinal data on the association
between Mets and CKD are reported in a non-Asiatic cohort of patients with T2D. Our 41%
incidence and 33% increased risk for development of low eGFR and albuminuria respectively
among patients with Mets (Fig 1) is in accordance with data from the literature [7]. In particu-
lar, the only prospective study published so far investigating the relationship between Mets
and incidence of CKD in 5,829 Chinese patients with T2D found a 31% higher risk of renal
outcome for subjects with Mets after a median follow-up duration of 4.6 years [9]. CKD was
defined as the first eGFR<60 ml/min per 1.73 m2 or the first hospitalization with CKD event,
adjudicated on the basis of hospital discharge diagnoses coded by the ICD-9.
Among the small number of prospective studies investigating the risk for developing either
microalbuminuria or dipstick-positive proteinuria among patients with Mets in non diabetic
patients [10–14], three studies showed a positive association, reporting a higher risk for pro-
teinuria in patients with Mets independently of gender [12, 14] or in men only [11].
An increase in SUA levels has repeatedly been demonstrated to be a risk factor for the
development of T2D [23, 24], and therefore the better glycemic control we describe among
patients with HU, as compared to those without it, seems counterintuitive (S1 Table) and
deserves further comment. As a matter of fact, an inverse correlation between SUA and
HbA1c levels has already been described in previous cross sectional studies on US and Chinese
populations [25, 26] and might be justified by a larger urine loss of uric acid in exchange for a
greater tubular handling of glucose due to glycosuria [27]. In fact, as suggested by studies on
patients with type 1 diabetes [28], a larger amount of glycosuria in patients with poor glycemic
control can lower SUA by decreasing uric acid reabsorption at the tubular level. Although the
molecular mechanisms underlying the uricosuric effect of glucose has not been completely elu-
cidated, interaction between glucose and urate transporters at the tubule level is highly plausi-
ble and might result in less renal uric acid reabsorption and lower serum levels [29].
On the contrary, higher insulin levels are known to reduce renal excretion of urate in both
healthy and hypertensive subjects [30], providing a strong mechanism supporting the previ-
ously described link between the Mets and HU [31, 32] and confirmed in the present cohort
where 74% of HU patients showed Mets (S1 Table). Interestingly, high SUA concentrations
commonly precede the development of insulin resistance in experimental studies [33, 34]
and frequently forerun the diagnosis of Mets in clinical reports [31, 35]. This has led several
authors to suggest that hyperuricemia may be a risk factor and a new marker for Mets. Data
presented herein support a role for SUA as a promoter of CKD, which in turn is a clinical con-
dition frequently associated to Mets [36]. In particular, our data suggest that relationship
between SUA values and both MS as well as the incidence of CKD extends even below the tra-
ditional cut-off used for hyperuricemia [37,38].
We observed increased ORs for new onset CKD along with the increasing number of base-
line MS components in agreement with previous reports [39, 40]. Hypertension is regarded as
the leading risk factor for development and progression of CKD in non-diabetic and diabetic
individuals and this is supported by our data showing that BP is the main risk factor for CKD
at univariate analysis. In fact, patients with BP >130/80 or antihypertensive treatment showed
a 3 times higher risk to develop low eGFR as compared to those without increased BP values.
Accordingly, after full adjustment, this single Mets component showed to be the strongest con-
tributor to the development of CKD increasing by as much as 57 and 35% the incidence of low
eGFR and albuminuria respectively during follow-up.
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While there are strong experimental and clinical data supporting the independent role of
increased SUA levels as a promoter of progression and development of CKD in T2D [16, 17],
the interaction between SUA and Mets has been much less investigated so far [32]. In this con-
text, our data indicate that SUA impact on renal outcomes is independent of the presence of
Mets and its components, thus supporting a link between Mets and renal damage at least in part
independent of hyperinsulinemia and its associates. To our knowledge, this is the first prospec-
tive study to investigate the combined role of Mets and HU on the incidence of CKD compo-
nents. HU increased significantly the risk of developing low eGFR in our study patients with
and without Mets, whereas the risk of albuminuria significantly increased only when Mets was
associated with HU (Table 2). Moreover, patients with both HU and Mets and patients with
either one of these risk factors showed greater eGFR reduction (adjusted for baseline eGFR)
over the entire study period as compared to those without HU and Mets (p<0.01).
These findings highlight the detrimental interaction of SUA and Mets at least in T2D.
In addition to high BP and hyperglycemia, several pathophysiological mechanism, includ-
ing insulin resistance, inflammation, oxidative stress, endothelial dysfunction, increased fruc-
tose intake, increased cytokine and adipokine synthesis and abnormalities in the sympathetic
nervous system, have all been suggested as important factors mediating glomerular and tubu-
lar fibrosis and vascular disease described in patients with Mets [41, 42]. While more studies
are needed to prove causality, these pathogenetic mechanisms support our findings of an
increased burden of renal risk in patients with T2D and Mets. Furthermore, our results add to
the existing body of literature about the harmful effects of Mets on the development of renal
damage and support the hypothesis that the frequent coexistence of Mets and HU might
explain part of the pathophysiological link between Mets and CKD in T2D.
Our study has some limitations as well as several strengths that should be mentioned. The
lack of data about waist circumference is a major limitation of the present analysis, especially
when one considers that in the presence of diabetes, low BMI may reflect lipolysis and muscle
wasting due to hyperglycemia and insufficient insulin action. Furthermore, the prognostic
information provided by BMI has been shown to vary depending on body composition and
clinical settings [43]. Although our analyses took into account several confounding variables,
we lacked data relating to physical activity, diet, socioeconomic status, diagnosis of gout and
family history of cardiovascular and kidney disease which might have influenced the results.
Furthermore, we did not gather specific information on urate lowering treatment. This, how-
ever, does not lessen the core message of our study, which deals with the prognostic power of
SUA values independent of confounding variables.
Moreover, we must acknowledge that laboratory parameters, including serum creatinine
were not measured in a centralized laboratory and this may have led to some variability, espe-
cially in GFR estimation. In addition, information on albuminuria has been gathered only as a
categorical trait and this may also have contributed to variability in the outcome measure.
On the other hand, the large size and homogeneous clinical characteristics of our study
cohort as well as the representative geographical distribution of the recruiting centers certainly
contribute to make our results a good representation of real life clinical condition.
4. Conclusions
In conclusion, Mets, its components and HU entail an increased risk for developing kidney
disease in patients with T2D. These results may be relevant to help focusing on better preven-
tion and therapeutic strategies as epidemiological surveys indicate increasing prevalence of
both Mets and HU and, accordingly, the burden of chronic renal disease remain a major health
concern in T2D.
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S1 Fig. Flow diagram for selection of study patients.
(TIFF)
S2 Fig. Incidence of GFR reduction on the basis of the presence/ absence of metabolic syn-
drome and the number of its components.
(TIFF)
S3 Fig. Incidence of albuminuria on the basis of the presence/ absence of metabolic syn-
drome and the number of its components.
(TIF)
S1 File. AMD ANNALS Study Group and Participating Centers.
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3. Kovács T, Vas T, Kovesdy CP, Késõi I, Sági B, Wittmann I, et al. Metabolic syndrome and other cardio-
vascular risk factors associated with the progression of IgA nephropathy. Clin Kidney J. 2013; 6: 395–
401. https://doi.org/10.1093/ckj/sfs131 PMID: 27293567
4. Navaneethan SD, Schold JD, Kirwan JP, Arrigain S, Jolly SE, Poggio ED, et al. Metabolic syndrome,
ESRD, and death in CKD. Clin J Am Soc Nephrol. 2013; 8: 945–952. https://doi.org/10.2215/CJN.
09870912 PMID: 23411425
5. Rashidi A, Ghanbarian A, Azizi F. Are patients who have metabolic syndrome without diabetes at risk
for developing chronic kidney disease? Evidence based on data from a large cohort screening popula-
tion. Clin J Am Soc Nephrol. 2007; 2: 976–983. https://doi.org/10.2215/CJN.01020207 PMID:
17702729
6. Kurella M, Lo JC, Chertow GM. Metabolic syndrome and the risk for chronic kidney disease among non-
diabetic adults. J Am Soc Nephrol. 2005; 16: 2134–2140. https://doi.org/10.1681/ASN.2005010106
PMID: 15901764
Metabolic syndrome, uric acid and DKD incidence
PLOS ONE | https://doi.org/10.1371/journal.pone.0176058 April 19, 2017 10 / 12
7. Thomas G, Sehgal AR, Kashyap SR, Srinivas TR, Kirwan JP, Navaneethan SD. Metabolic syndrome
and kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol. 2011; 6: 2364–
2373. https://doi.org/10.2215/CJN.02180311 PMID: 21852664
8. Leoncini G, Viazzi F, Agabiti Rosei E, Ambrosioni E, Costa FV, Leonetti G et al. Metabolic syndrome
and chronic kidney disease in high-risk Italian hypertensive patients: the I-DEMAND study. J Nephrol.
2012; 25: 63–74. https://doi.org/10.5301/JN.2011.7752 PMID: 21534241
9. Luk AO, So WY, Ma RC, Kong AP, Ozaki R, Ng VS, et al.; Hong Kong Diabetes Registry. Metabolic syn-
drome predicts new onset of chronic kidney disease in 5,829 patients with type 2 diabetes: a 5-year pro-
spective analysis of the Hong Kong Diabetes Registry. Diabetes Care. 2008; 31: 2357–2361. https://
doi.org/10.2337/dc08-0971 PMID: 18835954
10. Lucove J, Vupputuri S, Heiss G, North K, Russell M. Metabolic syndrome and the development of CKD
in American Indians: the Strong Heart Study. Am J Kidney Dis. 2008; 51: 21–28. https://doi.org/10.
1053/j.ajkd.2007.09.014 PMID: 18155529
11. Bonnet F, Marre M, Halimi JM, Stengel B, Lange C, Laville M, et al. Waist circumference and the metabolic
syndrome predict the development of elevated albuminuria in non-diabetic subjects: The DESIR Study. J
Hypertens 2006; 24: 1157–1163. https://doi.org/10.1097/01.hjh.0000226206.03560.ac PMID: 16685216
12. Tozawa M, Iseki C, Tokashiki K, Chinen S, Kohagura K, Kinjo K, et al. Metabolic syndrome and risk of
developing chronic kidney disease in Japanese adults. Hypertens Res. 2007; 30: 937–943. https://doi.
org/10.1291/hypres.30.937 PMID: 18049025
13. Sun F, Tao Q, Zhan S. Metabolic syndrome and the development of chronic kidney disease among 118
924 non-diabetic Taiwanese in a retrospective cohort. Nephrology (Carlton). 2010; 15: 84–92.
14. Watanabe H, Obata H, Watanabe T, Sasaki S, Nagai K, Aizawa Y:.Metabolic syndrome and risk of
development of chronic kidney disease: The Niigata Preventive Medicine Study. Diabetes Metab Res
Rev 2010; 26:26–32, https://doi.org/10.1002/dmrr.1058 PMID: 20014332
15. Lin WY, Liu CS, Li TC, Lin T, Chen W, Chen CC, et al. In addition to insulin resistance and obesity,
hyperuricemia is strongly associated with metabolic syndrome using different definitions in Chinese
populations: a population-based study (Taichung Community Health Study). Ann Rheum Dis 2008; 67:
432–433. https://doi.org/10.1136/ard.2007.073601 PMID: 18292110
16. Johnson RJ, Nakagawa T, Jalal D, Sánchez-Lozada LG, Kang DH, Ritz E. Uric acid and chronic kidney
disease: which is chasing which? Nephrol Dial Transplant. 2013; 28: 2221–2228. https://doi.org/10.
1093/ndt/gft029 PMID: 23543594
17. De Cosmo S, Viazzi F, Pacilli A, Giorda C, Ceriello A, Gentile S, et al.; AMD-Annals Study Group.
Serum Uric Acid and Risk of CKD in Type 2 Diabetes. Clin J Am Soc Nephrol. 2015; 10: 1921–1929.
https://doi.org/10.2215/CJN.03140315 PMID: 26342044
18. Chonchol M, Shlipak MG, Katz R, Sarnak MJ, Newman AB, Siscovick DS, et al. Relationship of uric
acid with progression of kidney disease. Am J Kidney Dis. 2007; 50: 239–247. https://doi.org/10.1053/j.
ajkd.2007.05.013 PMID: 17660025
19. Borghi C, Rosei EA, Bardin T, Dawson J, Dominiczak A, Kielstein JT, et al. Serum uric acid and the risk
of cardiovascular and renal disease. J Hypertens. 2015; 33: 1729–1741. https://doi.org/10.1097/HJH.
0000000000000701 PMID: 26136207
20. De Cosmo S, Rossi MC, Pellegrini F, Lucisano G, Bacci S, Gentile S, et al; AMD-Annals Study Group.
Kidney dysfunction and related cardiovascular risk factors among patients with type 2 diabetes. Nephrol
Dial Transplant. 2014; 29: 657–662. https://doi.org/10.1093/ndt/gft506 PMID: 24398892
21. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al.; CKD-EPI (Chronic
Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann
Intern Med. 2009; 150: 604–612. PMID: 19414839
22. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al.; International Diabetes
Federation Task Force on Epidemiology and Prevention; Hational Heart, Lung, and Blood Institute;
American Heart Association; World Heart Federation; International Atherosclerosis Society; Interna-
tional Association for the Study of Obesity: Harmonizing the metabolic syndrome: A joint interim state-
ment of the International diabetes federation task force on epidemiology and prevention; national heart,
lung, and blood institute; american heart association; world heart federation; international atherosclero-
sis society; and international association for the study of obesity. Circulation. 2009; 120: 1640–1645.
https://doi.org/10.1161/CIRCULATIONAHA.109.192644 PMID: 19805654
23. Viazzi F, Leoncini G, Vercelli M, Deferrari G, Pontremoli R. Serum uric acid levels predict new-onset
type 2 diabetes in hospitalized patients with primary hypertension: the MAGIC study. Diabetes Care.
2011; 34: 126–128. https://doi.org/10.2337/dc10-0918 PMID: 20921214
24. Lv Q, Meng XF, He FF, Chen S, Su H, Xiong J, et al. High serum uric acid and increased risk of type 2
diabetes: a systemic review and meta-analysis of prospective cohort studies. PLoS One. 2013; 8(2):
e56864. https://doi.org/10.1371/journal.pone.0056864 PMID: 23437258
Metabolic syndrome, uric acid and DKD incidence
PLOS ONE | https://doi.org/10.1371/journal.pone.0176058 April 19, 2017 11 / 12
25. Choi HK, Ford ES. Haemoglobin A1c, fasting glucose, serum C-peptide and insulin resistance in rela-
tion to serum uric acid levels—the Third National Health and Nutrition Examination Survey. Rheumatol-
ogy (Oxford). 2008; 47: 713–717.
26. Yan D, Tu Y, Jiang F, Wang J, Zhang R, Sun X, et al. Uric Acid is independently associated with diabetic
kidney disease: a cross-sectional study in a Chinese population. PLoS One. 2015 1; 10(6):e0129797.
https://doi.org/10.1371/journal.pone.0129797 PMID: 26029914
27. Mather A, Pollock C. Glucose handling by the kidney. Kidney Int Suppl. 2011; 120: S1–6.
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